Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.4K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.6K
T Cell Types and Functions01:24

T Cell Types and Functions

897
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
897
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

7.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
Master Transcription Regulators02:23

Master Transcription Regulators

6.8K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fusion gene heterogeneity and kinase enrichment in high-grade serous carcinomas.

Neoplasia (New York, N.Y.)·2026
Same author

High-Throughput Phenotypic Screen to Identify FoxP3 Regulators in Primary T Cells.

ACS chemical biology·2026
Same author

Precision cancer medicine in Europe: a mixed-methods study on infrastructure for extended molecular diagnostics.

Journal of cancer research and clinical oncology·2026
Same author

Merging clinical research and standard healthcare - Nordic Precision Cancer Medicine Symposium 2025.

Acta oncologica (Stockholm, Sweden)·2026
Same author

'Crossing borders' in data standardisation: application of OMOP CDM in an international clinical trial network in precision cancer medicine.

Acta oncologica (Stockholm, Sweden)·2026
Same author

A conceptual health economic modelling framework to assess the cost-effectiveness of molecular target-driven treatment regimens in oncology.

Acta oncologica (Stockholm, Sweden)·2026

Related Experiment Video

Updated: May 27, 2025

In Vitro Differentiation of Human CD4+FOXP3+ Induced Regulatory T Cells (iTregs) from Naïve CD4+ T Cells Using a TGF-β-containing Protocol
08:20

In Vitro Differentiation of Human CD4+FOXP3+ Induced Regulatory T Cells (iTregs) from Naïve CD4+ T Cells Using a TGF-β-containing Protocol

Published on: December 30, 2016

20.2K

MAPK and STAT3 Inhibitors Modulate FoxP3 Expression and Regulatory T Cell Function.

Nuria García-Díaz1,2, Elise Solli1,2, Ehsan Hajjar1

  • 1Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.

European Journal of Immunology
|February 16, 2025
PubMed
Summary

Researchers identified bosutinib and nifuroxazide as compounds that reduce regulatory T cells (Tregs) expressing FoxP3. These drugs and their analogs show promise for improving cancer immunotherapies by targeting these immune-suppressing cells.

Keywords:
MAPKSTAT3phenotypic drug screeningregulatory T cellssignal transduction

More Related Videos

Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation
15:33

Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation

Published on: August 13, 2013

15.8K
Determination of Regulatory T Cell Subsets in Murine Thymus, Pancreatic Draining Lymph Node and Spleen Using Flow Cytometry
08:06

Determination of Regulatory T Cell Subsets in Murine Thymus, Pancreatic Draining Lymph Node and Spleen Using Flow Cytometry

Published on: February 27, 2019

11.3K

Related Experiment Videos

Last Updated: May 27, 2025

In Vitro Differentiation of Human CD4+FOXP3+ Induced Regulatory T Cells (iTregs) from Naïve CD4+ T Cells Using a TGF-β-containing Protocol
08:20

In Vitro Differentiation of Human CD4+FOXP3+ Induced Regulatory T Cells (iTregs) from Naïve CD4+ T Cells Using a TGF-β-containing Protocol

Published on: December 30, 2016

20.2K
Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation
15:33

Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation

Published on: August 13, 2013

15.8K
Determination of Regulatory T Cell Subsets in Murine Thymus, Pancreatic Draining Lymph Node and Spleen Using Flow Cytometry
08:06

Determination of Regulatory T Cell Subsets in Murine Thymus, Pancreatic Draining Lymph Node and Spleen Using Flow Cytometry

Published on: February 27, 2019

11.3K

Area of Science:

  • Immunology
  • Cancer Biology
  • Pharmacology

Background:

  • Regulatory T cells (Tregs), identified by FoxP3 expression, are crucial for immune regulation.
  • Tregs accumulate in tumors, promoting cancer growth and hindering immune responses.
  • Targeting FoxP3+ Tregs presents a potential strategy to enhance cancer immunotherapies.

Purpose of the Study:

  • To identify compounds that downregulate FoxP3 expression in human primary T cells.
  • To discover novel therapeutic agents for improving cancer immunotherapy efficacy.

Main Methods:

  • High-throughput phenotypic screening of a drug repurposing library.
  • Identification and validation of compounds and their structural analogs targeting FoxP3 expression.
  • Assessment of compound effects on Treg suppressive functions and activation markers.
  • Analysis of specific signaling pathways (FAK, CaMKII, STAT3) modulated by the compounds.

Main Results:

  • Bosutinib and nifuroxazide were identified as effective inhibitors of FoxP3 expression in Tregs.
  • Structural analogs of bosutinib and nifuroxazide demonstrated similar or enhanced potency in downregulating FoxP3.
  • All tested compounds inhibited Treg suppressive functions and reduced Treg activation markers.
  • Bosutinib preferentially disrupted FAK and CaMKII signaling, while nifuroxazide and NA16 targeted STAT3.
  • Bosutinib and NA16 showed greater efficacy against effector Tregs compared to other Treg subsets.

Conclusions:

  • Bosutinib, nifuroxazide, and their analogs effectively inhibit FoxP3 expression and Treg functions.
  • These compounds represent promising tools for enhancing current cancer immunotherapy strategies.
  • Targeting Tregs via FoxP3 downregulation offers a viable approach for cancer treatment.